Cardiovascular prevention: Frontiers in lipid guidelines

Area of Science:

• Cardiology
• Biochemistry
• Genetics

Background:

• Cardiovascular disease (CVD) is a leading global cause of death.
• Guidelines are updating with new evidence, economic factors, and expiring drug patents.
• Research is exploring novel biomarkers and risk factors for CVD prediction.

Purpose of the Study:

• To review current evidence on lipid fractions and biomarkers for CVD risk.
• To discuss advancements in CVD risk calculators and genetic detection of familial hypercholesterolemia.
• To evaluate the role of novel lipid-lowering therapies and omega-3 fatty acids in CVD management.

Main Methods:

• Literature review of recent trials and studies on CVD risk factors and treatments.
• Analysis of data on lipid fractions, novel biomarkers, and genetic testing.
• Examination of international guidelines and economic considerations for lipid-lowering therapies.

Main Results:

• Low-density lipoprotein cholesterol (LDL-C) remains central, with statins and ezetimibe established treatments.
• Novel therapies like PCSK9 inhibitors show promise but require further evaluation.
• The role of other lipid fractions and omega-3 fatty acids in CVD requires clarification.

Conclusions:

• Evolving evidence necessitates updated CVD guidelines and risk assessment tools.
• Personalized approaches, including genetic screening, are becoming more prominent.
• Further research is needed to fully integrate new lipid data and therapies into clinical practice.